mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia

We have previously demonstrated that mTOR inhibitors (MTIs) are active in preclinical models of acute lymphoblastic leukemia (ALL). MTIs may increase degradation of cyclin D1, a protein involved in dihydrofolate reductase (DHFR) synthesis. Because resistance to methotrexate may correlate with high D...

Full description

Saved in:
Bibliographic Details
Main Authors: Teachey, David T., Sheen, Cecilia, Hall, Junior, Ryan, Theresa, Brown, Valerie I., Fish, Jonathan, Reid, Gregor S. D., Seif, Alix E., Norris, Robin, Chang, Yueh J., Carroll, Martin, Grupp, Stephan A.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2008
Subjects:
Neoplasia
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2518903/
https://ncbi.nlm.nih.gov/pubmed/18544682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-137141
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items